| Name | Title | Contact Details |
|---|
Portola Pharmaceuticals is dedicated to developing and commercializing therapies that transform patient lives and advance patient care by changing treatment paradigms in thrombosis and other hematologic diseases. Our two lead assets are Bevyxxa® (betrixaban), and andexanet alfa. In addition, cerdulatinib is our investigational Syk/JAK inhibitor to treat hematologic cancers. These compounds come from our own internal research efforts and represent important advances to address significant unmet needs. We are employing novel strategies that may increase the likelihood of clinical, regulatory and commercial success of our potentially lifesaving therapies.
United BioSource Corporation is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.
First Primary Care is a direct primary care practice that provides personalized, accessible, cost-effective, modern care to each member of your family. They offer unrestricted, no-wait access to primary care physicians through in-person visits, text, o...
Quiq, Inc. is a Blue Bell, PA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Kaysville Clinic is a Layton, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.